Retroperitoneal sarcomas (RPS) are rare tumors for which complete surgical resection remains the mainstay of treatment. The objective of the current study was to determine the impact of hospital case volume on outcomes in patients with RPS. METHODS: A total of 6950 patients with primary RPS who underwent surgical resection were identified from the National Cancer Data Base (1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011). Treating hospitals were classified by annual case volume; low-volume hospitals (LVHs) and high-volume hospitals (HVHs) were defined as those with ≤10 cases per year and >10 cases per year, respectively. Overall survival (OS) was compared using Kaplan-Meier curves. Cox proportional hazard models were created to compare risks. RESULTS: Of the 1131 reporting hospitals, the majority (1127 hospitals; 99.6%) were LVHs treating the majority of patients (6270 patients; 90.2%). Patients treated at LVHs were more likely to have lower grade and smaller tumors, receive radiotherapy, and undergo incomplete macroscopic (R2) resection. Patients treated at HVHs had lower 30-day readmission rates (1.8% vs 3.4%; P<.001), 30-day (1.9% vs 3.1%; P=.004) and 90-day (3.2% vs 5.7%; P=.007) mortality, longer median OS (76.2 months vs 64.2 months; P<.001), and higher 5-year OS rates (58% vs 52%; P<.001). After controlling for age, sex, insurance status, tumor size, tumor grade, surgical resection margin status, and radiotherapy administration, treatment at an HVH was found to be independently associated with a reduced risk of death (hazard ratio, 0.77; 95% confidence interval, 0.65-0.91 [P=.003]). CONCLUSIONS: Primary RPS are rare tumors, and to our knowledge few surgeons and institutions have significant experience and expertise in their multidisciplinary management and surgical resection. Although additional studies are needed, patient outcomes may be impacted by the case volume and expertise of the treating facility. Cancer 2018;124:4495-4503.
INTRODUCTION
Soft-tissue sarcomas (STS) are rare and heterogeneous tumors for which the mainstay of treatment for primary localized disease is complete surgical resection. Of the 12,390 new cases of STS diagnosed in the United States in 2017, 1 approximately 15% will present in the retroperitoneum. 2 Retroperitoneal sarcomas (RPS) pose significant technical challenges for the surgeon given their typically large size and abutment or involvement of adjacent critical structures. Surgical resection of these tumors most often necessitates multiorgan resection and vascular reconstruction, and achieving a macroscopically complete surgical (R0/R1) resection often is difficult.
European and North American expert sarcoma surgeons in conjunction with the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group have published consensus statements to describe a reproducible and standardized approach to these tumors, 3 in which they and others recommend that patients with RPS be managed by experienced multidisciplinary teams in specialized sarcoma referral centers. [3] [4] [5] Whether treatment at specialized referral centers and high-volume hospitals (HVHs) compared with low-volume hospitals (LVHs) is associated with better cancer outcomes has been the subject of many studies across disease sites [6] [7] [8] [9] [10] [11] and in patients undergoing complex oncologic surgical resections, including head/neck surgery, 12 radical cystectomy, 13 lung resection,
Cancer December 1, 2018 retroperitoneum); 21 2) included patients who did not undergo RPS surgical resection; 22 and 3) often defined hospitals performing as few as 5 RPS resections per year as HVHs. 21, 22 The objective of the current study was to determine the impact of hospital case volume on outcomes among patients who underwent surgical resection of primary RPS using a large national cancer database.
MATERIALS AND METHODS

Data Source
The National Cancer Data Base (NCDB) is a hospitalbased cancer registry sponsored by the American College of Surgeons and the American Cancer Society that prospectively captures approximately 70% of all new cancer cases in the United States. The data include clinicopathologic, treatment, and outcome variables and are deidentified. Therefore, the current study was considered exempt by The University of Texas MD Anderson Cancer Center institutional review board.
Analytic Cohort
Patients diagnosed with primary RPS (1998-2011) were identified from the NCDB Participant Use File (12,423 patients) using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) code C480 (Fig. 1) . All histologic subtypes included in the data were vetted individually to exclude nonsarcomatous or mixed histologies (see Supporting Table 1) . 23 Additional subgroups excluded from the analytical cohort were patients who did not undergo surgical resection, pediatric patients, patients with central nervous system and bone sarcomas, patients not treated at the reporting hospital, and patients with incomplete information. The final study cohort (6950 patients) was grouped by hospital volume into LVHs (≤10 cases/year) or HVHs (>10 cases/year) ( Table 1) . We chose not to use the median number of RPS surgical resections performed per year by reporting hospitals as a cutoff value with which to define LVHs versus HVHs because the median number of cases per year was only 1.1. Furthermore, hospitals performing 2 cases per year were among the 90th percentile and those performing 5.4 cases per year were among the 99th percentile. Thus, we defined 10 RPS resections per year as a cutoff value for LVHs versus HVHs because we believed this volume would endow a hospital with sufficient experience and expertise in the treatment of these rare tumors. Using receiver operating characteristic curves, we were unable to identify a better cutoff value with which to define LVHs versus HVHs (data not shown).
Study Variables
Study variables included patient age, sex, race, income, educational level, insurance status, Charlson-Deyo Score, treating facility type (academic, comprehensive, or community), hospital volume (number of cases/year reporting to the NCDB), tumor grade, tumor size, and therapies received including radiotherapy and/or chemotherapy. In the NCDB, income is estimated by the median household income in the zip code of each patient's area of residence based on the 2012 American Community Survey data. Educational attainment is estimated by the number of adults in the patient's zip code who graduated from high school based on the 2012 American Community Survey data. Outcomes of interest included rates of complete (R0/R1) RPS surgical resection, 30-day readmission, 30-day mortality, 90-day mortality, and overall survival (OS).
Statistical Analysis
Survival data were available for the years 1998 through 2011. The Kaplan-Meier method and log-rank test were used to calculate and compare the unadjusted OS curves by hospital volume. Univariate and multivariate Cox regression models were used to identify covariates associated with OS. Age, sex, race, insurance status, tumor size, surgical resection margin, tumor grade, radiotherapy, and hospital volume were considered in the univariate Cox regression models; a stepwise method was used to select the final multivariate models. All variables (except chemotherapy administration) included in the model met the proportional hazards function assumption with the exclusion of unknown cases from the analysis except for chemotherapy administration, which consistently violated the proportional hazards assumption. Therefore, 2 separate models for OS were performed: 1) one for all patients, stratified by chemotherapy status; and 2) one model for patients who did not receive chemotherapy. The adjusted survival curves were estimated from the final Cox regression models after adjusting for significant covariates. We performed a logistic regression analysis to determine factors predictive of treatment at an LVH (see Supporting Table 2 ). We next performed sensitivity analyses to evaluate the reliability of our model. Propensity score methods (propensity score stratification, normalized weighting, and covariate adjustment) were applied to the Cox regression model (see Supporting Table 3) with hospital volume as the dependent variable and age at diagnosis, sex, race, insurance status, and educational level as independent variables. The resulting hazard ratios (HRs) were similar to those of the original model and thus this model was retained as our final model. A P value <.05 was considered to be statistically significant.
SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) was used to conduct all analyses.
RESULTS
The Majority of Patients With Primary RPS Are Treated at LVHs
Between 1998 and 2011, a total of 1131 reporting hospitals performed surgical resections for patients with primary RPS (Table 1 ). The vast majority of reporting hospitals (1127 hospitals; 99.6%) were LVHs that performed ≤10 primary RPS resections per year. Of the total of 6950 patients with primary RPS who underwent surgical resection during the study period, the majority were treated at LVHs (6270 patients; 90.2%). A minority of patients (680 patients; 9.8%) were treated at the 4 HVHs, defined as facilities that averaged >10 cases per year. Although the number of surgical cases performed for RPS steadily increased from 1998 to 2011, the percentage of surgical resections performed at HVHs remained relatively constant (range, 7.6%-12.2%) over the study period (Fig. 2 ) (see Supporting Table 4 ).
Patients Treated at LVHs Versus HVHs Differ With Regard to Their Baseline Characteristics and Treatment Modalities
Patient demographics and clinical characteristics and by treating hospital volume are detailed in Cancer December 1, 2018 differences between subgroups of patients treated at LVHs versus HVHs. There were notable socioeconomic differences between patients with RPS who were treated at LVHs versus those treated at HVHs. Patients treated at LVHs were more likely to be ethnic minorities rather than white and to be of lower educational background and income (all P<.001). In addition, LVHs treated a greater percentage of uninsured patients (3.2% vs 1.2%) or patients with Medicaid/Medicare (45.4% vs 28%) (P<.001).
HVHs also were distinct from LVHs with respect to patient clinical and tumor characteristics and the multidisciplinary treatment modalities used. HVHs treated patients with RPS that were larger (P=.048) and of high tumor grade (P<.001), features that are reported to be associated with poorer clinical outcomes. 4, 24, 25 Those treated at HVHs waited longer between diagnosis and the initiation of treatment (median of 28 days vs 5 days; P<.001) and between diagnosis and definitive surgical resection (median of 36 days vs 10 days; P<.001). HVHs were less likely to use radiotherapy (17.2% vs 27.9%; P<.001), although the use of systemic therapy was similar between LVHs and HVHs.
Primary RPS Treatment at HVHs Is Associated With Improved Outcomes
We next compared the outcomes of patients who underwent surgical resection for primary RPS at LVHs versus HVHs. One of the most important prognostic factors for patients with RPS is the ability to resect all macroscopic disease (R0/R1 surgical resection). Surgery at HVHs was associated with fewer incomplete (R2) macroscopic resections (1.6% vs 4.5%; P<.001).
Compared with patients treated at LVHs, those treated at HVHs had lower 30-day readmission rates (1.8% vs 3.4%; P<.001), 30-day mortality (1.9% vs 3.1%; P=.004), and 90-day mortality (3.2% vs 5.7%; P=.007) ( Table 1) . Treatment of RPS at HVHs also was found to be associated with a longer median OS (76.2 months vs 64.2 months) and 5-year OS rate (57.7% vs 52.0%) (Fig.  3) . Additional analyses have suggested a dose effect associated with increasing hospital case volume and better patient outcomes and found progressive improvements in patient outcome with increasing hospital case volume (0-5 cases/year, 6-10 cases/year, and >10 cases/year) (see Supporting Fig. 1 ). Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; OS, overall survival; R0/R1, complete macroscopic resection; R2, incomplete macroscopic resection; RPS, retroperitoneal sarcoma.
Cancer December 1, 2018 To examine whether hospital volume was independently associated with OS, univariate and multivariate Cox regression models were used to identify covariates associated with OS. Chemotherapy as a covariate violated the proportional hazards assumption in the model. Patients who received chemotherapy (959 patients; 13.8%) differed significantly with respect to multiple factors compared with those patients who did not receive chemotherapy (5763 patients; 82.9%) as part of their multidisciplinary treatment plan (see Supporting  Table 5 ). Thus, analysis was limited to patients who did not receive chemotherapy as part of treatment of their RPS (see Supporting Table 6 ).
On multivariate analysis, treatment at an HVH was found to be associated with a reduced risk of death compared with treatment at an LVH (HR, 0.77; 95% confidence interval, 0.65-0.91 [P=.003]) ( Table 2 ). Older age, male sex, larger tumor size, higher tumor grade, and incomplete macroscopic (R2) surgical resection also were associated with worse OS. We found similar results for univariate and multivariate analyses to identify factors predictive of OS among all patients, stratified by chemotherapy status (see Supporting Table 7 ). We also found similar results when separate analyses were performed that were limited to patients for whom a Charlson-Deyo Score was available in the NCDB (2003-2011; 3524 patients) (see Supporting Table 8) .
DISCUSSION
In the current study, we examined the effect of hospital case volume on perioperative and survival outcomes in patients undergoing surgical resection for primary RPS using the NCDB. The results of the current study demonstrate that the treatment of primary RPS at HVHs is associated with reduced perioperative death and improved OS. Unfortunately, however, the vast majority of primary RPS surgical resections occurring during the study period were performed at LVHs that had limited experience in the multidisciplinary care of these rare tumors. It is important to note that although a cutoff value of 10 RPS surgical resections per year (<1 case/month) was chosen for LVHs versus HVHs herein, expert sarcoma referral centers likely have higher volumes than this cutoff value.
To our knowledge, the current study is the first to investigate the impact of hospital volume on outcomes among patients undergoing surgical resection for RPS. Although 2 prior studies examined hospital volume and outcomes in patients with sarcoma, these studies were limited for several reasons. 21, 22 Gutierrez et al reported outcomes among 4205 patients with STS who were undergoing surgical resection, and demonstrated lower 30-day and 90-day mortality in patients treated at HVHs. 21 However, the majority of patients included had STS of the extremity, trunk, and head and neck, and <42% of patients included had RPS. 21 Also using the NCDB, Maurice et al reported outcomes among 3141 patients with RPS. However, approximately 30% of patients in this study did not undergo surgical resection and an HVH was defined as a hospital performing at least 5 surgical resections per year. 22 Although RPS treatment at HVHs in this study was associated with higher rates of surgical resection and R0/R1 surgical resection, the authors did not find a survival difference between patients treated at HVHs and those treated at LVHs.
Although to our knowledge the association between hospital volume and patient outcomes has begun to be examined only recently for patients with sarcomas, it has been extensively examined across other patient populations. [6] [7] [8] 11, 20, 26 Compared with treatment at LVHs, treatment at HVHs has been associated with improved patient outcomes after various complex oncologic resections, including head and neck surgery, 12 esophagectomy, 9, 15, 16 colorectal surgery, 9,17,27 HPB, 9, 19, 20, 28 cystectomy, 13 nephrectomy, 10 and major lung resection. 14 The relationship between hospital volume and patient outcomes may reflect differences in multiple aspects of the multidisciplinary care of the oncology patient undergoing complex surgical resection, such as the patient with primary resectable RPS. These may include not only differences in surgeon volume and experience at HVHs, which Cancer December 1, 2018 may result in differences in the surgical approach to RPS surgical resection, completeness of surgical resection, and quality of surgery, but also may extend to differences with regard to how multimodality therapy is used, how patients are surveyed, and how disease recurrence is managed.
The impact of surgeon volume on patient outcomes has been demonstrated in other patient populations such as after adrenalectomy, 29 thyroidectomy, 30 and HPB surgery. 18, 31 In the current study, despite the limitations of the data available in the NCDB regarding perioperative complications, there were immediate differences noted with regard to quality of surgery, with higher rates of incomplete (R2) RPS surgical resection occurring at LVHs compared with HVHs. In addition, there were significant differences observed regarding the use of radiotherapy for patients with RPS between HVHs and LVHs. Finally, surgical resection at HVHs compared with LVHs is associated with significantly lower 30-day readmission.
There also are data available across disease sites to suggest that HVHs may be better able to "rescue" patients after postoperative complications. Failure to rescue (FTR) is defined as surgical mortality after a major perioperative complication and has been demonstrated to differ between HVHs and LVHs in other patient populations, including patients undergoing high-risk cancer operations such as gastrectomy, esophagectomy, pancreatectomy, and liver resection. 18, [32] [33] [34] Although FTR could not be determined in the current study using the data available in the NCDB, it might be extrapolated that LVHs may have had higher FTR rates based on the findings of higher 30-day and 90-day mortality rates.
Lastly, studies have suggested that there may be differences in rates of adherence to sarcoma treatment guidelines between HVHs and LVHs. Incomplete adherence to sarcoma treatment guidelines consistently has been shown to be associated with worse outcomes in studies of patient populations in the United States 35 and Europe. 36, 37 Furthermore, these studies report that treatment received within specialized sarcoma centers, within HVHs, and within a cancer network is more likely to adhere to treatment guidelines. [38] [39] [40] Despite a significant body of literature demonstrating the association between care at HVHs and improved outcomes, a significant percentage of patients seek care at LVHs. Although some patients may prefer to undergo a complex surgical procedure at a local LVH, 41 there is concern that socioeconomic barriers may prevent many patients from accessing care at HVHs and specialized referral centers. 20, 42, 43 In the current study, demographic data available in the NCDB suggest that patients who underwent surgery at LVHs may be of lower socioeconomic status, raising concerns that socioeconomic circumstances may be barriers to a patient's ability to access care at HVHs for the treatment of RPS.
There are several limitations to the current study, including those inherent to retrospective studies using a large national database. Data available through the NCDB are submitted by participating hospitals across the United States and therefore not only reflect potential differences in RPS management across institutions but also may reflect inconsistencies in the pathologic diagnosis of RPS histologies and data entry by research personnel. Furthermore, for each variable examined, a minority of cases within the analytic cohort had data that were missing or insufficient for analysis. In addition, the NCDB does not include data pertaining to disease recurrence/progression, systemic chemotherapy administered, or radiotherapy regimens. However, despite these limitations, the NCDB remains a valuable resource with which to study patient-related and hospital-related factors that may impact patient care and oncologic outcomes, particularly in patients with rare malignancies such as primary RPS.
CONCLUSIONS
Multidisciplinary care of the patient with RPS is complex. Although additional studies are needed, the results of the current study suggest that outcomes among patients with primary RPS who are undergoing surgical resection may be impacted by the case volume and experience of the treating facility. Furthermore, patients who underwent surgery at LVHs in the current study were of lower socioeconomic status, raising concerns that financial and social circumstances may be clinically relevant barriers to an individual's ability to seek and access care at HVHs for the treatment of RPS. 
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